<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Epidemiology and Infectious Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Epidemiology and Infectious Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Эпидемиология и инфекционные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">3034-2007</issn><issn publication-format="electronic">3034-2015</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">679793</article-id><article-id pub-id-type="doi">10.17816/EID679793</article-id><article-id pub-id-type="edn">OWLJCD</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Guillain–Barré syndrome associated with COVID-19: a case report</article-title><trans-title-group xml:lang="ru"><trans-title>Синдром Гийена–Барре, ассоциированный с COVID-19: клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-1656-9056</contrib-id><name-alternatives><name xml:lang="en"><surname>Shahriyari Moghaddam</surname><given-names>Reyhaneh</given-names></name><name xml:lang="ru"><surname>Шахрияри Могхаддам</surname><given-names>Рийханех</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Rey.sha@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-2479-9090</contrib-id><name-alternatives><name xml:lang="en"><surname>Salnikova</surname><given-names>Ekaterina E.</given-names></name><name xml:lang="ru"><surname>Сальникова</surname><given-names>Екатерина Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ekaterina.salnikova.71@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5669-1910</contrib-id><contrib-id contrib-id-type="spin">4487-6744</contrib-id><name-alternatives><name xml:lang="en"><surname>Voznesenskiy</surname><given-names>Sergey L.</given-names></name><name xml:lang="ru"><surname>Вознесенский</surname><given-names>Сергей Леонидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>voznesenskiy-sl@rudn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-7262-7791</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanova</surname><given-names>Olga A.</given-names></name><name xml:lang="ru"><surname>Иванова</surname><given-names>Ольга Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>olga.mart.safonova@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Peoples' Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов им. П. Лумумбы</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Infectious Diseases Clinical Hospital № 1</institution></aff><aff><institution xml:lang="ru">Инфекционная клиническая больница № 1</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-12-31" publication-format="electronic"><day>31</day><month>12</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-02-24" publication-format="electronic"><day>24</day><month>02</month><year>2026</year></pub-date><volume>30</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>247</fpage><lpage>253</lpage><history><date date-type="received" iso-8601-date="2025-05-16"><day>16</day><month>05</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-11-28"><day>28</day><month>11</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-vector</copyright-holder><copyright-holder xml:lang="ru">Эко-вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-02-24"/></permissions><self-uri xlink:href="https://rjeid.com/1560-9529/article/view/679793">https://rjeid.com/1560-9529/article/view/679793</self-uri><abstract xml:lang="en"><p>Guillain–Barré syndrome is an acute and rapidly progressive autoimmune disease that affects the peripheral nervous system. The major manifestations are limb paresthesia, muscle weakness, and/or flaccid paralysis. The disease is often associated with previous infections, such as respiratory or gastrointestinal ones. During the COVID-19 pandemic, evidence emerged suggesting that over 30% of patients infected with SARS-CoV-2 presented with neurological symptoms. These symptoms may appear at various stages of the disease and include headache, muscle pain, nausea, vomiting, loss of smell (anosmia), and loss of taste (ageusia). However, COVID-19 can also cause more severe complications such as encephalomyelitis, acute myelitis, thromboembolic disorders, ischemic stroke, intracerebral hemorrhage, Guillain–Barré syndrome, Bell’s palsy, and rhabdomyolysis. Guillain–Barré syndrome is characterized by a rapid progression of muscle weakness that can lead to respiratory muscle paralysis and respiratory failure, requiring immediate medical intervention. The article reports a clinical case of Guillain–Barré syndrome associated with COVID-19. This case report emphasizes the importance of prompt diagnosis of neurological complications in patients with COVID-19 to improve prognosis and reduce the risk of long-term complications.</p></abstract><trans-abstract xml:lang="ru"><p>Синдром Гийена–Барре — острое, быстро прогрессирующее аутоиммунное заболевание периферической нервной системы. Его основными проявлениями служат парестезии конечностей, мышечная слабость и/или вялые параличи. Заболевание часто ассоциировано с предшествующими инфекционными заболеваниями, например, респираторными или желудочно-кишечными. На фоне пандемии коронавирусной инфекции (COVID-19) появились данные, свидетельствующие, что более чем у 30% пациентов с SARS-CoV-2 наблюдают неврологические симптомы. Эти симптомы могут возникать на разных этапах заболевания и включают головную боль, миалгию, тошноту, рвоту, аносмию (потерю обоняния) и агевзию (потерю вкуса). Однако COVID-19 также способен вызывать более тяжёлые осложнения, такие как энцефаломиелит, острый миелит, тромбоэмболические нарушения, ишемический инсульт, внутримозговое кровоизлияние, синдром Гийена–Барре, паралич Белла и рабдомиолиз. Для синдрома Гийена–Барре характерна быстро прогрессирующая мышечная слабость, которая приводит к параличу дыхательной мускулатуры и развитию дыхательной недостаточности, что требует немедленного медицинского вмешательства. В статье описан клинический случай синдрома Гийена–Барре, ассоциированного с COVID-19. Описание данного случая подчёркивает важность ранней диагностики неврологических осложнений у пациентов с новой коронавирусной инфекцией для улучшения прогноза и снижения риска долгосрочных последствий.</p></trans-abstract><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>Guillain-Barre syndrome</kwd><kwd>polyneuropathies</kwd><kwd>case report</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>синдром Гийена–Барре</kwd><kwd>полинейропатия</kwd><kwd>клинический случай</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">при поддержке Программы стратегического академического лидерства РУДН</institution></institution-wrap><institution-wrap><institution xml:lang="en">RUDN University Strategic Academic Leadership Program</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Hasan I, Salf-Ur-Rahman KM, Hayat SH, et al. Guillain–Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis. J Peripher Nerv Syst. 2020;25(4):335–343. doi: 10.1111/jns.12419 EDN: CUOKQD</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021;268(4):1133–1170. doi: 10.1007/s00415-020-10124-x EDN: MOSFVW</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574–2576. doi: 10.1056/NEJMc2009191 EDN: LWITIO</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–482. doi: 10.1038/nrneurol.2014.121</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–683. doi: 10.1038/s41582-019-0250-9</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ministry of Health of the Russian Federation. Clinical guidelines: Guillain–Barré syndrome. [Internet]. Moscow; 2020. [cited 2025 Dec 9] Available from: https://share.google/RzCh5dZCfb9FXT4ZQ</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hughes RAC, Cornblath DR. Guillain–Barré syndrome. Lancet. 2005;366(9497):1653–1666. doi: 10.1016/S0140-6736(05)67665-9</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain–Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33–43. doi: 10.1093/brain/awt285</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain–Barré syndrome. Neurology. 2011;76(11):968–975. doi: 10.1212/WNL.0b013e3182104407</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhao H, Shen D, Zhou H, et al. Guillain–Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383–384. doi: 10.1016/S1474-4422(20)30109-5 EDN: TNYZXJ</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain–Barré syndrome. Cochrane Database Syst Rev. 2017;2017(2):CD001798. doi: 10.1002/14651858.CD001798.pub3</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767–783. doi: 10.1016/S1474-4422(20)30221-0 EDN: NHXSTC</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi: 10.1001/jamaneurol.2020.1127 EDN: XQSUQA </mixed-citation></ref></ref-list></back></article>
